| Title: |
The utility of P300 as a schizophrenia endophenotype and predictive biomarker: Clinical and socio-demographic modulators in COGS-2 |
| Authors: |
Turetsky, BI; Dress, EM; Braff, DL; Calkins, ME; Green, MF; Greenwood, TA; Gur, RE; Gur, RC; Lazzeroni, LC; Nuechterlein, KH; Radant, AD; Seidman, LJ; Siever, LJ; Silverman, JM; Sprock, J; Stone, WS; Sugar, CA; Swerdlow, NR; Tsuang, DW; Tsuang, MT; Light, G |
| Source: |
Schizophrenia Research, vol 163, iss 1-3 |
| Publisher Information: |
eScholarship, University of California |
| Publication Year: |
2015 |
| Collection: |
University of California: eScholarship |
| Subject Terms: |
Medical and Health Sciences; Psychology and Cognitive Sciences; Psychiatry |
| Subject Geographic: |
53 - 62 |
| Description: |
Reduced auditory P300 amplitude is a robust schizophrenia deficit exhibiting the qualities of a viable genetic endophenotype. These include heritability, test-retest reliability, and trait-like stability. Recent evidence suggests that P300 may also serve as a predictive biomarker for transition to psychosis during the schizophrenia prodrome. Historically, the utility of the P300 has been limited by its clinical nonspecificity, cross-site measurement variability, and required EEG expertise. The Consortium on the Genetics of Schizophrenia (COGS-2) study provided an opportunity to examine the consistency of the measure across multiple sites with varying degrees of EEG experience, and to identify important modulating factors that contribute to measurement variability. Auditory P300 was acquired from 649 controls and 587 patients at 5 sites. An overall patient deficit was observed with effect size 0.62. Each site independently observed a significant patient deficit, but site differences also existed. In patients, site differences reflected clinical differences in positive symptomatology and functional capacity. In controls, site differences reflected differences in racial stratification, smoking and substance use history. These factors differentially suppressed the P300 response, but only in control subjects. This led to an attenuated patient-control difference among smokers and among African Americans with history of substance use. These findings indicate that the P300 can be adequately assessed quantitatively, across sites, without substantial EEG expertise. Measurements are suitable for both genetic endophenotype analyses and studies of psychosis risk and conversion. However, careful attention must be given to selection of appropriate comparison samples to avoid misleading false negative results. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
qt8f38d6t3; https://escholarship.org/uc/item/8f38d6t3; https://escholarship.org/content/qt8f38d6t3/qt8f38d6t3.pdf |
| DOI: |
10.1016/j.schres.2014.09.024 |
| Availability: |
https://escholarship.org/uc/item/8f38d6t3; https://escholarship.org/content/qt8f38d6t3/qt8f38d6t3.pdf; https://doi.org/10.1016/j.schres.2014.09.024 |
| Rights: |
public |
| Accession Number: |
edsbas.EF26F522 |
| Database: |
BASE |